- Funds will accelerate wide-scale adoption and commercialisation of biocement® technology
- Supports goal to eliminate 25% of global carbon emissions from the concrete industry by 2030
Copenhagen, Denmark – 28 February 2022 – Novo Holdings, a leading international life sciences investor, today announces it has participated in the US$65 million Series C financing in Biomason, the only company in the world employing biotechnology to commercially produce cement. The financing will enable the Company to accelerate development of its proprietary biocement® technology platform to reach its goal of eliminating 25% of global carbon emissions from the concrete industry by 2030. Novo Holdings first invested in Biomason in 2019 leading the Company’s Series B financing round, and the continued support for the Company reflects Novo Holdings’ vision to create more sustainable solutions in industry and construction through biology.